Glaucoma Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Glaucoma Epidemiology Forecast Report Coverage

Expert Market Research's “Glaucoma Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of glaucoma. It projects the future incidence and prevalence rates of glaucoma cases across various populations. The study covers age, gender, and type as major determinants of the glaucoma population. The report highlights patterns in the prevalence of glaucoma over time and projects future trends based on multiple variables.

Glaucoma Understanding: Disease Overview

Glaucoma represents a group of progressive optic neuropathies characterized by retinal ganglion cell loss and visual field damage, commonly associated with elevated intraocular pressure (IOP). It is a leading cause of irreversible blindness worldwide. Primary open-angle glaucoma is the most prevalent type, followed by angle-closure and secondary glaucomas. Risk factors include aging, family history, corticosteroid use, and African or Asian ethnicity. Because early stages are asymptomatic, regular screening is essential for timely detection and vision preservation.

Glaucoma Epidemiology Perspective

The glaucoma epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the glaucoma epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for glaucoma and their trends. The glaucoma detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• In 2022, the global incidence of primary open-angle glaucoma (POAG) among adults aged 40-79 years was 23.46 per 10,000 person-years, indicating a substantial burden among middle-aged and older populations.
• A 2014 systematic review projected that the number of people aged 40-80 with glaucoma worldwide would be 64.3 million in 2013, increasing to 76.0 million in 2020 and to ~111.8 million by 2040.
• In meta-analyses, age is consistently one of the strongest risk factors. Age-specific incidence rises sharply, from 5.51 per 10,000 in adults 40-44 to 64.36 per 10,000 in those 75-79, demonstrating the pronounced impact of advancing age on glaucoma risk.
• Globally, glaucoma tends to affect men slightly more than women, though the gap is narrowing, as the prevalence among women has steadily increased over the past few decades.

Read more about this report - Request a Free Sample

Country-wise Glaucoma Epidemiology Segment

The glaucoma epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, glaucoma affects an estimated 4.22 million adults (approximately 1.62% of the population aged 18 and older) as of 2022, highlighting its significance as a public health concern. The condition impacts both men and women, with females accounting for about 2.29 million and males for 1.94 million individuals. While often asymptomatic in early stages, glaucoma can lead to irreversible vision loss if undetected. Continued efforts in screening, early diagnosis, and management are essential to mitigate the burden of this chronic eye disease and preserve population eye health.

Glaucoma: Treatment Overview

Glaucoma management aims to reduce IOP and prevent optic nerve damage. First-line therapy includes topical medications such as prostaglandin analogs, beta-blockers, or carbonic anhydrase inhibitors. Laser procedures, including trabeculoplasty and iridotomy, are employed when medical therapy is insufficient. Surgical interventions like trabeculectomy or minimally invasive glaucoma surgery (MIGS) are reserved for advanced disease. Continuous monitoring and adherence are critical, as glaucoma is a lifelong condition. Novel neuroprotective and sustained-release drug delivery systems are under active investigation.

Key Questions Answered

• What are the key findings of glaucoma epidemiology in the 8 major markets?
• What will be the total number of patients with glaucoma across the 8 major markets during the forecast period?
• What was the country-wise glaucoma epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of glaucoma during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of glaucoma during the forecast period of 2026-2035?
• What are the currently available treatments for glaucoma?
• What are the disease risks, signs, symptoms, and unmet needs of glaucoma?

Scope of the Glaucoma Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of glaucoma based on several factors.
• Glaucoma Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The glaucoma report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Glaucoma Therapeutics Market

Uveitic Glaucoma Market